Latest Research And Development News

Page 9 of 115
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026
SCX.ai has reported positive operating cash flow in its first quarter as an ASX-listed company, alongside a 54% increase in annualised recurring revenue since its prospectus. The sovereign AI infrastructure provider also has more than 100 commercial customers and $23.9 million in cash, but its next test is converting new capacity and partnerships into durable revenue.
Sophie Babbage
Sophie Babbage
27 Oct 2026
Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.
Ada Torres
Ada Torres
27 Oct 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
Radiopharm Theranostics has received an $8 million advance against its anticipated FY26 Australian R&D tax incentive, giving the clinical-stage company additional funding for trials and working capital. The facility carries commercial interest and must be repaid by 26 October 2027.
Victor Sage
Victor Sage
26 Oct 2026
Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
Ada Torres
Ada Torres
26 Oct 2026
ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.
Victor Sage
Victor Sage
26 Oct 2026
Island Pharmaceuticals has secured approvals to use Galidesivir in Uganda’s Bundibugyo Ebola outbreak while advancing two complementary Marburg studies and expanding manufacturing. The progress comes with a sharper funding question: cash fell to A$7.83 million after quarterly operating outflows of A$4.93 million, leaving an estimated 1.6 quarters of funding.
Victor Sage
Victor Sage
26 Oct 2026
Firebird Metals has improved the packing density, particle morphology and impurity profile of its lithium-manganese-rich precursor material, with tap density reaching 1.35 g/cm³ and sulphur falling 46% to 610 ppm. The results strengthen the technical case for the platform, but downstream cathode testing and larger-scale validation remain ahead.
Victor Sage
Victor Sage
26 Oct 2026
FINEOS lifted its quarterly client receipts 47% and ended September with €51.7 million in cash, while maintaining FY26 revenue guidance of €147 million to €152 million. The stronger cash position was helped by the delayed collection of approximately €8 million in invoices, but no new sales were finalised during the quarter.
Victor Sage
Victor Sage
26 Oct 2026
EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.
Victor Sage
Victor Sage
26 Oct 2026
Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.
Victor Sage
Victor Sage
26 Oct 2026

Browse the archive

Full archive